Thermo Fisher Scientific Inc. $TMO Stock Acquired by Ferguson Wellman Capital Management Inc.

Key Points

• Ferguson Wellman Capital Management increased its Thermo Fisher Scientific stake by 11.9% in the third quarter, bringing its holdings to 86,904 shares valued at approximately $58.7 million. Institutional investors and hedge funds collectively own 89.23% of TMO.
• Thermo Fisher reported quarterly earnings of $6.03 per share, exceeding estimates of $5.71, while revenue rose 10.5% year over year to $11.99 billion. The company maintained fiscal 2026 earnings guidance of $24.93–$25.33 per share.
• TMO shares recently traded at $666.86, near their 52-week high, while analysts hold a consensus “Moderate Buy” rating with an average price target of $628.78. Insiders sold 73,768 shares worth about $44.1 million over the past three months.

Ferguson Wellman Capital Management Inc. raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 11.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 86,904 shares of the medical research company's stock after buying an additional 9,275 shares during the quarter. Ferguson Wellman Capital Management Inc.'s holdings in Thermo Fisher Scientific were worth $58,665,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Violich Capital Management Inc. boosted its stake in Thermo Fisher Scientific by 21.4% during the third quarter. Violich Capital Management Inc. now owns 1,335 shares of the medical research company's stock worth $901,000 after buying an additional 235 shares during the last quarter. Polaris Financial Partners acquired a new stake in Thermo Fisher Scientific during the third quarter worth about $32,000. Global Wealth Strategies & Associates acquired a new position in Thermo Fisher Scientific in the 3rd quarter valued at about $271,000. Versant Capital Management Inc increased its stake in Thermo Fisher Scientific by 35.8% during the third quarter. Versant Capital Management Inc now owns 1,165 shares of the medical research company's stock worth $786,000 after acquiring an additional 307 shares during the last quarter. Finally, Burkett Financial Services LLC purchased a new stake in Thermo Fisher Scientific in the 3rd quarter valued at about $65,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Thermo Fisher Scientific

In related news, VP Lisa P. Britt sold 11,440 shares of the firm's stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the transaction, the vice president owned 14,784 shares in the company, valued at $9,064,366.08. This trade represents a 43.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CAO Joseph R. Holmes sold 420 shares of the stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the sale, the chief accounting officer directly owned 2,966 shares of the company's stock, valued at $1,734,546.46. The trade was a 12.40% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 73,768 shares of company stock worth $44,122,820. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Up 1.8%

Shares of TMO traded up $12.06 during midday trading on Monday, reaching $666.86. The stock had a trading volume of 631,973 shares, compared to its average volume of 2,243,463. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The company's fifty day simple moving average is $618.62 and its two-hundred day simple moving average is $535.16. The company has a market cap of $246.57 billion, a price-to-earnings ratio of 35.87, a PEG ratio of 2.74 and a beta of 0.87. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $683.63.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company had revenue of $11.99 billion for the quarter, compared to analysts' expectations of $11.71 billion. During the same period last year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific's quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 25.13 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific's payout ratio is currently 10.11%.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on TMO shares. Royal Bank Of Canada increased their price objective on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a "sector perform" rating in a research report on Friday, July 24th. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a research note on Friday, June 26th. They set a "market perform" rating and a $520.00 target price on the stock. Evercore set a $570.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, July 6th. Piper Sandler initiated coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, September 9th. They issued an "overweight" rating for the company. Finally, Morgan Stanley increased their target price on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an "overweight" rating in a report on Friday, July 24th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and a consensus price target of $628.78.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company's portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.